Search
Acinetobacter baumannii
Epidemiology:
- common, nosocomial, highly drug resistant, gram-negative pathogen
Pathology:
- causes with pneumonia
Laboratory:
- Acinetobacter baumannii DNA
Management:
1) imipenem/cilastin
2) colistin for resistant organisms [1]
3) Carbapenem-resistant Acinetobacter baumannii
- durlobactam sulbactam in combination with meropenem or imipenem-cilastatin [3]
General
Acinetobacter
Properties
KINGDOM: monera
DIVISION: SCHIZOMYCETES
References
- Journal Watch 23(13):104, 2003
- Garnacho-Montero J et al
Treatment of multidrug-resistant Acinetobacter baumannii
ventilator-associated pneumonia (VAP) with intravenous
colistin: a comparison with imipenem-susceptible VAP.
Clin Inect Dis 36:1111, 2003
- Centers for Disease Control and Prevention (CDC)
Acinetobacter baumannii infections among patients at military
medical facilities treating injured U.S. service members,
2002-2004.
MMWR Morb Mortal Wkly Rep. 2004 Nov 19;53(45):1063-6.
PMID: 15549020
- Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA.
Infectious Diseases Society of America 2024 Guidance on the Treatment of
Antimicrobial-Resistant Gram-Negative Infections.
Clin Infect Dis. 2024 Aug 7:ciae403.
PMID: 39108079
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae403/7728556